Comparison Between Propofol and Fentanyl for Prevention of Emergence Agitation in Children After Sevoflurane Anesthesia

NCT ID: NCT01506622

Last Updated: 2015-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

222 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-01-31

Study Completion Date

2011-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The occurrence of emergence agitation (EA) in pediatric patients who have received sevoflurane anesthesia is a common postoperative problem. The prevalence of EA varies between 10% to 80% depending on the scoring system for evaluation and the anesthetic technique used.

Many authors reported various strategies such as use of sedative premedication, change of maintenance technique of anesthesia, or pharmacological agents administered at the end of anesthesia to reduce the incidence and severity of EA, and to allow a smooth emergence from sevoflurane anesthesia. Among these strategies, the use of pharmacological agents at the end of anesthesia is not affected by anesthetic duration, and may not prolong recovery duration of anesthesia excessively when these agents are administered as subhypnotic or small dose. The typical agents that can be administered in this way are propofol and fentanyl.

Previous studies demonstrated that the use of either propofol or fentanyl at the end of anesthesia could reduce the incidence of EA.

The purpose of this study is to compare the preventive effect on EA and the characteristics of anesthesia recovery between propofol and fentanyl administered at the end of sevoflurane anesthesia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Emergence Agitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Propofol group

intravenous administration of propofol 1 mg/kg at the end of anesthesia

Group Type ACTIVE_COMPARATOR

Administration of propofol

Intervention Type DRUG

Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.

Fentanyl group

intravenous administration of fentanyl 1 mcg/kg at the end of anesthesia

Group Type ACTIVE_COMPARATOR

Administration of fentanyl

Intervention Type DRUG

Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.

Control group

intravenous administration of saline at the end of anesthesia

Group Type ACTIVE_COMPARATOR

Administration of saline

Intervention Type DRUG

Saline will be administered to control group at the end of anesthesia.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Administration of propofol

Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.

Intervention Type DRUG

Administration of fentanyl

Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.

Intervention Type DRUG

Administration of saline

Saline will be administered to control group at the end of anesthesia.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* American Society of Anesthesiologists I or II,
* 18-72 months of age,
* scheduled for ambulatory inguinal hernia repair undergoing general sevoflurane anesthesia

Exclusion Criteria

* developmental delay
* psychological and neurologic disorder
* sedatives medication
* an abnormal airway
* reactive airway disease
* extreme agitation and uncooperation
* previous history of anesthesia
Minimum Eligible Age

18 Months

Maximum Eligible Age

72 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yonsei University

Seoul, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

References

Explore related publications, articles, or registry entries linked to this study.

Chen J, Li W, Hu X, Wang D. Emergence agitation after cataract surgery in children: a comparison of midazolam, propofol and ketamine. Paediatr Anaesth. 2010 Sep;20(9):873-9. doi: 10.1111/j.1460-9592.2010.03375.x.

Reference Type BACKGROUND
PMID: 20716081 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

4-2010-0536

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Emergence Agitation of Sevoflurane in Pediatric
NCT06830564 COMPLETED PHASE2/PHASE3
Emergency Agitation in T&A
NCT01152476 COMPLETED NA
Scalp Nerve Block on Emergence Agitation
NCT02428283 COMPLETED PHASE4
Sevoflurane Induced Emergence Agitation
NCT02022488 COMPLETED PHASE4
Propofol in Emergence Agitation
NCT00535613 COMPLETED PHASE4